Activation of MET pathway predicts poor outcome to cetuximab in patients with recurrent or metastatic head and neck cancer
about
Hepatocyte Growth Factor/c-Met Signaling in Head and Neck Cancer and Implications for TreatmentDual-receptor (EGFR and c-MET) inhibition by tumor-suppressive miR-1 and miR-206 in head and neck squamous cell carcinoma.Treatment of head and neck cancer in the elderly.Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal junction cancer (RILOMET-1): a randomised, double-blind, placebo-controlled, phase 3 trial.Activated HGF-c-Met Axis in Head and Neck Cancer.Clinicopathological impacts of high c-Met expression in head and neck squamous cell carcinoma: a meta-analysis and review.A Phase 1 study evaluating AMG 337 in Asian patients with advanced solid tumors.IL6 is associated with response to dasatinib and cetuximab: Phase II clinical trial with mechanistic correlatives in cetuximab-resistant head and neck cancer.BET inhibition overcomes receptor tyrosine kinase-mediated cetuximab resistance in HNSCC.MET alterations detected in blood-derived circulating tumor DNA correlate with bone metastases and poor prognosis.Nuclear Klf4 accumulation is associated with cetuximab drug-resistance and predicts poor prognosis of nasopharyngeal carcinoma.Cell-Free DNA Profiling to Discover Mechanisms of Exceptional Response to Cabozantinib Plus Panitumumab in a Patient With Treatment Refractory Metastatic Colorectal Cancer
P2860
Q33607965-C3F009D6-52C8-4831-8755-204AF9D6ECE0Q38771636-27EE9E87-665D-4DD1-99E9-3473351550F2Q38958367-9065D229-A9EE-4EF0-B743-902F3760DF5EQ42693879-484B1D9A-B283-4689-ABB0-8F4F6BEEBDB1Q47303095-8690CCF4-A336-4C90-9FB8-DB0B6742774CQ49414583-05AB4B10-B53B-48DB-A35F-3D03599267B5Q50958892-652A3C38-6110-4B1F-8F69-3937F26E5016Q53258023-9D954173-807A-4CAF-9135-2EBA54205389Q54978430-6AC29DEB-B395-411B-80CB-ED7EE13AC444Q55491411-FAFEC2D6-A875-4F3B-9556-93B82A2DD18DQ55518643-12FD4247-E8A3-4AAD-87FD-E46806687614Q58698130-547E64EA-2440-49CE-8161-A7B46C09979B
P2860
Activation of MET pathway predicts poor outcome to cetuximab in patients with recurrent or metastatic head and neck cancer
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Activation of MET pathway pred ...... etastatic head and neck cancer
@ast
Activation of MET pathway pred ...... etastatic head and neck cancer
@en
type
label
Activation of MET pathway pred ...... etastatic head and neck cancer
@ast
Activation of MET pathway pred ...... etastatic head and neck cancer
@en
prefLabel
Activation of MET pathway pred ...... etastatic head and neck cancer
@ast
Activation of MET pathway pred ...... etastatic head and neck cancer
@en
P2093
P2860
P1476
Activation of MET pathway pred ...... etastatic head and neck cancer
@en
P2093
Cristina Caramés
Cristina Chamizo
Eduardo Gavín
Ion Cristóbal
Jesús García-Foncillas
Juan Madoz-Gúrpide
Sandra Zazo
Victoria Casado
P2860
P2888
P356
10.1186/S12967-015-0633-7
P577
2015-08-29T00:00:00Z
P5875
P6179
1013548438